<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K3L4M3" height="0" width="0" style="display:none;visibility:hidden">

Flat White

Are health regulators turning a blind eye to puberty blockers?

19 June 2023

5:00 AM

19 June 2023

5:00 AM

With a never-ending increase in red tape across the healthcare industry, you might be surprised to learn that ‘gender-affirming care’ for children appears to be escaping strict regulation.

In Senate Estimates, the Therapeutic Goods Administration (TGA) confirmed they are happy to vacate the field on the administration of puberty blockers and cross-sex hormones to children, admitting they see no need to micromanage the prescription of such drugs off-label.

As reported by The Australian, Therapeutic Goods Administration Chief Medical adviser Robyn Langham was asked about the regulation of puberty blockers being prescribed off-label to children as young as 10 years old.

Professor Langham said it...

Already a subscriber? Log in

Get 10 issues
for $20

Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $20.

  • Delivery of the weekly magazine
  • Unlimited access to spectator.com.au and app
  • Spectator podcasts and newsletters
  • Full access to spectator.co.uk
Or

Unlock this article

REGISTER


Comments

Don't miss out

Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.

Already a subscriber? Log in

Close